These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12475345)

  • 21. Determination of indomethacin polymorphic contents by chemometric near-infrared spectroscopy and conventional powder X-ray diffractometry.
    Otsuka M; Kato F; Matsuda Y
    Analyst; 2001 Sep; 126(9):1578-82. PubMed ID: 11592653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphic Transformation of Indomethacin during Hot Melt Extrusion Granulation: Process and Dissolution Control.
    Xu T; Nahar K; Dave R; Bates S; Morris K
    Pharm Res; 2018 May; 35(7):140. PubMed ID: 29748722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphism of Indomethacin in Semicrystalline Dispersions: Formation, Transformation, and Segregation.
    Van Duong T; Lüdeker D; Van Bockstal PJ; De Beer T; Van Humbeeck J; Van den Mooter G
    Mol Pharm; 2018 Mar; 15(3):1037-1051. PubMed ID: 29307188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions.
    Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
    Int J Pharm; 2018 Jun; 544(1):172-180. PubMed ID: 29669257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A High Energy X-ray Diffraction Study of Amorphous Indomethacin.
    Benmore CJ; Benmore SR; Edwards AD; Shrader CD; Bhat MH; Cherry BR; Smith P; Gozzo F; Shi C; Smith D; Yarger JL; Byrn SR; Weber JKR
    J Pharm Sci; 2022 Mar; 111(3):818-824. PubMed ID: 34890631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase characterization of indomethacin in binary solid dispersions with PVP VA64 or Myrj 52.
    Wang X; de Armas HN; Blaton N; Michoel A; Van den Mooter G
    Int J Pharm; 2007 Dec; 345(1-2):95-100. PubMed ID: 17604923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solid-state characteristics of amorphous sodium indomethacin relative to its free acid.
    Tong P; Zografi G
    Pharm Res; 1999 Aug; 16(8):1186-92. PubMed ID: 10468018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy.
    Heinz A; Savolainen M; Rades T; Strachan CJ
    Eur J Pharm Sci; 2007 Nov; 32(3):182-92. PubMed ID: 17716878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
    Fini A; Cavallari C; Ospitali F
    Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphic transformation of indomethacin under high pressures.
    Okumura T; Ishida M; Takayama K; Otsuka M
    J Pharm Sci; 2006 Mar; 95(3):689-700. PubMed ID: 16432876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of sorbed water on the crystallization of indomethacin from the amorphous state.
    Andronis V; Yoshioka M; Zografi G
    J Pharm Sci; 1997 Mar; 86(3):346-51. PubMed ID: 9050804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystal and molecular structure of the ammonium salt of the dinucleoside monophosphate d(CpG).
    Ramakrishnan B; Viswamitra MA
    J Biomol Struct Dyn; 1988 Dec; 6(3):511-23. PubMed ID: 3271536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphism on leflunomide: stability and crystal structures.
    Vega D; Petragalli A; Fernández D; Ellena JA
    J Pharm Sci; 2006 May; 95(5):1075-83. PubMed ID: 16570307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.
    Beyer A; Radi L; Grohganz H; Löbmann K; Rades T; Leopold CS
    Eur J Pharm Biopharm; 2016 Jul; 104():72-81. PubMed ID: 27130786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure determination, thermal stability and dissolution rate of δ-indomethacin.
    Andrusenko I; Hamilton V; Lanza AE; Hall CL; Mugnaioli E; Potticary J; Buanz A; Gaisford S; Piras AM; Zambito Y; Hall SR; Gemmi M
    Int J Pharm; 2021 Oct; 608():121067. PubMed ID: 34481012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystal structure and possible catalytic mechanism of microsomal prostaglandin E synthase type 2 (mPGES-2).
    Yamada T; Komoto J; Watanabe K; Ohmiya Y; Takusagawa F
    J Mol Biol; 2005 May; 348(5):1163-76. PubMed ID: 15854652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using the low-frequency Raman spectroscopy to analyze the crystallization of amorphous indomethacin.
    Hédoux A; Paccou L; Guinet Y; Willart JF; Descamps M
    Eur J Pharm Sci; 2009 Sep; 38(2):156-64. PubMed ID: 19591926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
    Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
    Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spectroscopic Investigation of the Formation and Disruption of Hydrogen Bonds in Pharmaceutical Semicrystalline Dispersions.
    Van Duong T; Reekmans G; Venkatesham A; Van Aerschot A; Adriaensens P; Van Humbeeck J; Van den Mooter G
    Mol Pharm; 2017 May; 14(5):1726-1741. PubMed ID: 28363028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphs of tamoxifen citrate: detailed structural characterization of the stable form.
    Goldberg I; Becker Y
    J Pharm Sci; 1987 Mar; 76(3):259-64. PubMed ID: 3585745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.